EyeCRO specializes in preclinical ophthalmic studies to examine the efficacy of novel test agents and therapeutic modalities. Our models are well established and optimized to facilitate generation of reproducible datasets with meaningful endpoints.
With over two decades of experience in vision research, our expert scientists can help you select the right model and experimental design to achieve your research and development goals. We also offer Toxicology/PK studies, and eyedrop formulations in MiDROPS™.
The Global Leader in Preclinical Ophthalmic Research
Microemulsion Drug Ocular Penetration System MiDROPS™
MiDROPS™ was developed to allow for eyedrop formulation of small molecules that are lipophilic. This technology represents a fundamentally new approach for ophthalmic drug delivery using microemulsions which are thermodynamically stable. These self-assembling vehicles can formulate high concentrations of drugs and deliver them in abundant quantities to both the anterior segment and posterior segment. Our broad patents are issued in the US and Worldwide and protect millions of different formulations covered in our library.
Click here to learn more about this innovative platform technology
Models
News & Events
EyeCRO on Twitter
SparingVision Raises €44.5 Million for Gene-Independent RP Therapy https://www.fightingblindness.org/research/sparingvision-raises-44-5-million-for-gene-independent-rp-therapy-141
We MUST reject attacks on our public health scientists and institutions (@US_FDA @CDCgov ) as we fight the #covid19 pandemic. If you agree, please like, retweet, and provide your support! https://go.nature.com/34hBWBc
Some have voiced concern that a #COVID19 vaccine might cause people to develop more severe disease when they encounter the virus. A paper by the #NIH #ACTIV Vaccines Working Group addresses why it’s unlikely vaccine-associated enhanced disease will occur: https://bit.ly/3m2M8U9
